trending Market Intelligence /marketintelligence/en/news-insights/trending/ssnngjc3witjfg8grvv-iq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

OncoSil Medical closes institutional placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

OncoSil Medical closes institutional placement

OncoSil Medical Ltd. closed the first tranche of its previously announced non-underwritten institutional placement of 106.1 million shares.

The company issued 72.7 million shares at 12 Australian cents each in the first tranche, raising A$8.7 million.

OncoSil will issue 33.3 million shares at the same price under the second tranche, for proceeds of about A$4 million. The second tranche is subject to shareholder approval at a May 4 meeting.

Wilsons Corporate Finance Ltd. is managing the institutional placement.

Australia-based OncoSil is a late-stage medical device company that develops localized cancer treatments.